Candel Therapeutics Inc (CADL)

Currency in USD
13.14
-0.37(-2.70%)
Real-time Data·
Advertisement
CADL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.0013.38
52 wk Range
4.3513.82
Key Statistics
Prev. Close
13.5
Open
13.23
Day's Range
13-13.38
52 wk Range
4.35-13.82
Volume
193.93K
Average Volume (3m)
1.65M
1-Year Change
142.8058%
Book Value / Share
1.72
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CADL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.88
Upside
+58.87%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

Candel Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.88
(+58.87% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Freedom Broker
Buy15.00+15.12%14.00Maintain17/08/2026
BofA Securities
Hold12.00-7.90%9.00Maintain14/08/2026
H.C. Wainwright
Buy23.00+76.52%-Maintain29/07/2026
Stifel
Buy22.00+68.84%-New Coverage13/07/2026
BofA Securities
Hold9.00-30.93%7.00Maintain18/05/2026

Earnings

Latest Release
13/08/2026
EPS / Forecast
-0.52 / -0.23
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare CADL to Peers and Sector

Metrics to compare
CADL
Peers
Sector
Relationship
P/E Ratio
−11.7x−3.8x−0.3x
PEG Ratio
0.06−0.040.00
Price/Book
8.2x2.3x2.6x
Price / LTM Sales
-21.5x3.1x
Upside (Analyst Target)
66.7%114.9%48.5%
Fair Value Upside
Unlock−11.3%6.3%Unlock

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
22.01M30.04%297.16M
Other Institutional Investors
35.03M47.80%472.85M
Public Companies & Retail Investors
16.23M22.15%219.13M
Total
73.27M100.00%989.15M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC15.00%10,986,917148,323
RTW Investments, LP8.76%6,422,01886,697

People Also Watch

8.1000
AKTX
+2.53%
29.62
BRX
-0.40%
4.06
CURR
+0.28%
0.6741
ONCO
-5.19%

FAQ

What Is the Candel Therapeutics (NASDAQ: CADL) Share Price Today?

The Candel Therapeutics stock price today is 13.14 USD.

What Stock Exchange Does Candel Therapeutics (CADL) Trade On?

Candel Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Candel Therapeutics?

The stock symbol (also called a 'ticker') for Candel Therapeutics is "CADL."

What Is the Current Candel Therapeutics Market Capitalisation?

As of today, Candel Therapeutics (NASDAQ: CADL) market cap is 1.01B USD.

What Is Candel Therapeutics's (CADL) Earnings Per Share (TTM)?

The Candel Therapeutics EPS is currently -1.44 (Trailing Twelve Months).

When Is the Next Candel Therapeutics Earnings Date?

Candel Therapeutics's next earnings report will be released on 05/11/2026.

Is CADL a Buy or Sell From a Technical Analyst Perspective?

Based on today's Candel Therapeutics moving averages and other technical indicators, the daily buy/sell signal for CADL stock is Strong Buy.

How Many Times Has Candel Therapeutics Stock Split?

Candel Therapeutics has split 0 times. (See the CADL stock split history page for full effective split date and price information.)

How Many Employees Does Candel Therapeutics Have?

Candel Therapeutics has 55 employees, based on their latest Companies House report.

What is the current trading status of Candel Therapeutics (NASDAQ: CADL)?

As of 20/08/2026, Candel Therapeutics (CADL) is trading at a share price of 13.14 USD, with a previous close of 13.50 USD. The stock has fluctuated within a day range of 13.00 USD to 13.38 USD, while its 52-week range spans from 4.35 USD to 13.82 USD.

What Is Candel Therapeutics (CADL) Price Target According to Analysts?

The average 12-month price target for Candel Therapeutics is 20.88 USD, with a high estimate of 29 USD and a low estimate of 12 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +58.87% Upside potential.

What Is the CADL Premarket Price?

CADL's last pre-market stock price is 13.25 USD. The pre-market share volume is 6,840.00, and the stock has decreased by -0.25, or -1.85%.

What Is the CADL After Hours Price?

CADL's last after hours stock price is 13.32 USD, the stock has decreased by -0.18, or -1.33%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.